Catalog Number | CBCL-594 |
Price | Online Inquiry |
Unit Quantity | 1x106 cells / 1.0 ml |
Stable T47D cell clone resistant to CDK4/6 inhibitors
Drug screening and biological assays
Palbociclib, branded as Ibrance, is a selective inhibitor of cyclin-dependent inhibitor of CDK4 and CDK6, and was approved for treatment of HR-positive and HER2 negative breast cancer.
Species | Human |
Host Cell Line | T47D cell line |
Cell Type | Mammary gland epithelial cells |
Stability | Stable in culture over 10 passages |
Growth Properties | Adherent |
Pharmaceutical Target | Immune Molecules |
Recommended Medium | RPMI1640 + 10% FBS + 0.2 U/ml insulin + 5 μM Palbociclib |
Selection Marker | |
Morphology | Epithelial |
Seeding Density | Thaw entire contents into an appropriate T25 flask. |
Subculture Ratio | Recommended a ratio of 1:3-1:5. |
Storage Method | Frozen in liquid nitrogen with 70% medium, 20% FBS and 10% DMSO |
Doubling Time | |
QC | WB |
Biosafety Level | BSL-1 |
Shipping | Shipping in dry ice |
Caution | For Research Use Only |